• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

具有治疗潜力的新型肽类抗生素。

Emerging peptide antibiotics with therapeutic potential.

作者信息

Upert Gregory, Luther Anatol, Obrecht Daniel, Ermert Philipp

机构信息

Polyphor Ltd, Hegenheimermattweg 125, 4123 Allschwil, Switzerland.

Bachem AG, Hauptstrasse 114, 4416 Bubendorf, Switzerland.

出版信息

Med Drug Discov. 2021 Mar;9:100078. doi: 10.1016/j.medidd.2020.100078. Epub 2020 Dec 30.

DOI:10.1016/j.medidd.2020.100078
PMID:33398258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7773004/
Abstract

This review covers some of the recent progress in the field of peptide antibiotics with a focus on compounds with novel or established mode of action and with demonstrated efficacy in animal infection models. Novel drug discovery approaches, linear and macrocyclic peptide antibiotics, lipopeptides like the polymyxins as well as peptides addressing targets located in the plasma membrane or in the outer membrane of bacterial cells are discussed.

摘要

本综述涵盖了肽类抗生素领域的一些最新进展，重点关注具有新型或已确定作用模式且在动物感染模型中已证明具有疗效的化合物。讨论了新型药物发现方法、线性和大环肽类抗生素、多粘菌素等脂肽以及针对位于细菌细胞质膜或外膜中的靶点的肽类。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/8bf240b231ce/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/91aa17e57509/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/8f27a4621f90/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/5be8a97459b1/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/63dfa7979c54/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/ef71eb30830e/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/abd4381c1371/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/008d9e0d5b22/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/c3f979fe50a9/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/dce7f79bf085/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/23e3d271ac11/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/dbfe617ab8fe/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/0c17777a9d58/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/a8d0895e403c/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/bb56f1ec19e7/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/8bf240b231ce/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/91aa17e57509/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/8f27a4621f90/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/5be8a97459b1/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/63dfa7979c54/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/ef71eb30830e/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/abd4381c1371/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/008d9e0d5b22/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/c3f979fe50a9/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/dce7f79bf085/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/23e3d271ac11/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/dbfe617ab8fe/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/0c17777a9d58/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/a8d0895e403c/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/bb56f1ec19e7/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f081/7773004/8bf240b231ce/gr15_lrg.jpg

相似文献

1
Emerging peptide antibiotics with therapeutic potential.具有治疗潜力的新型肽类抗生素。
Med Drug Discov. 2021 Mar;9:100078. doi: 10.1016/j.medidd.2020.100078. Epub 2020 Dec 30.
2
Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital.尼泊尔一家医院中ESKAPE病原体的特征分析，特别关注多重耐药性和生物膜形成
Infect Drug Resist. 2021 Jun 14;14:2201-2212. doi: 10.2147/IDR.S306688. eCollection 2021.
3
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.舒巴坦钠：一种用于治疗多重耐药菌引起的尿路感染的静脉注射和口服青霉素类药物。
Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16.
4
The helical propensity of KLA amphipathic peptides enhances their binding to gel-state lipid membranes.KLA 两亲性肽的螺旋倾向增强了它们与凝胶态脂质膜的结合。
Biophys Chem. 2013 Oct-Nov;180-181:10-21. doi: 10.1016/j.bpc.2013.05.003. Epub 2013 May 24.
5
Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.经典β-内酰胺酶抑制剂增强达托霉素对耐甲氧西林金黄色葡萄球菌的活性以及黏菌素对鲍曼不动杆菌的活性。
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01745-16. Print 2017 Feb.
6
Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.新型喹唑啉-4(3H)-酮衍生物的合成与评价，作为抗多药耐药金黄色葡萄球菌和结核分枝杆菌的有效抗菌剂。
Eur J Med Chem. 2019 Aug 1;175:287-308. doi: 10.1016/j.ejmech.2019.04.067. Epub 2019 Apr 28.
7
Nanotechnology as a therapeutic tool to combat microbial resistance.纳米技术作为一种治疗工具，用于对抗微生物耐药性。
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15. doi: 10.1016/j.addr.2013.07.011. Epub 2013 Jul 24.
8
Spectral and biological evaluation of a synthetic antimicrobial peptide derived from 1-aminocyclohexane carboxylic acid.源自1-氨基环己烷羧酸的合成抗菌肽的光谱及生物学评估
Bioorg Med Chem. 2015 Mar 15;23(6):1341-7. doi: 10.1016/j.bmc.2015.01.027. Epub 2015 Jan 22.
9
A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.全细胞筛选发现与多粘菌素协同作用并具有抗多重耐药菌活性的小分子生物活性物质。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01677-19.
10
Effect of membrane composition on antimicrobial peptides aurein 2.2 and 2.3 from Australian southern bell frogs.膜组成对来自澳大利亚南部铃蟾的抗菌肽奥瑞金2.2和2.3的影响。
Biophys J. 2009 Jan;96(2):552-65. doi: 10.1016/j.bpj.2008.10.012.

引用本文的文献

1
Colloidal Structure Dictates Antimicrobial Efficacy in LL-37 Self-Assemblies With Glycerol Monooleate.胶体结构决定了LL-37与单油酸甘油酯自组装体中的抗菌效果。
Small. 2024 Dec;20(51):e2405131. doi: 10.1002/smll.202405131. Epub 2024 Oct 15.
2
A Chronicle Review of Approaches for Discovering Novel Antimicrobial Agents to Combat Antimicrobial Resistance.对抗耐药性的新型抗菌药物发现方法编年史回顾
Indian J Microbiol. 2024 Sep;64(3):879-893. doi: 10.1007/s12088-024-01355-x. Epub 2024 Jul 22.
3
Cell-Free Systems: Ideal Platforms for Accelerating the Discovery and Production of Peptide-Based Antibiotics.

本文引用的文献

1
NMR structure and localization of the host defense antimicrobial peptide thanatin in zwitterionic dodecylphosphocholine micelle: Implications in antimicrobial activity.NMR 结构与阳离子十二烷基磷酸胆碱胶束中宿主防御抗菌肽 thanatin 的定位：对抗菌活性的影响。
Biochim Biophys Acta Biomembr. 2020 Nov 1;1862(11):183432. doi: 10.1016/j.bbamem.2020.183432. Epub 2020 Aug 8.
2
Total Synthesis of Malacidin A by β-Hydroxyaspartic Acid Ligation-Mediated Cyclization and Absolute Structure Establishment.通过β-羟基天冬氨酸连接介导的环化反应实现 Malacidin A 的全合成及其绝对结构确定。
Angew Chem Int Ed Engl. 2020 Nov 2;59(45):19868-19872. doi: 10.1002/anie.202009092. Epub 2020 Aug 31.
3
无细胞系统：加速基于肽的抗生素发现和生产的理想平台。
Int J Mol Sci. 2024 Aug 22;25(16):9109. doi: 10.3390/ijms25169109.
4
Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target.脂多糖转运（Lpt）系统的结构见解作为一种新的抗生素靶标。
J Microbiol. 2024 Apr;62(4):261-275. doi: 10.1007/s12275-024-00137-w. Epub 2024 May 31.
5
Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.朋友还是敌人？应对多重耐药/广泛耐药革兰氏阴性菌的新型抗菌药物：一项系统综述
Front Microbiol. 2024 May 10;15:1385475. doi: 10.3389/fmicb.2024.1385475. eCollection 2024.
6
Synthesis of the Antimicrobial Peptide Murepavadin Using Novel Coupling Agents.使用新型偶联剂合成抗菌肽 Murepavadin。
Biomolecules. 2024 Apr 27;14(5):526. doi: 10.3390/biom14050526.
7
First report of multidrug-resistant carbapenemase-producing co-harboring and .首次报告产碳青霉烯酶的多重耐药菌 同时携带 和 。
Microbiol Spectr. 2024 May 2;12(5):e0368523. doi: 10.1128/spectrum.03685-23. Epub 2024 Mar 21.
8
Metagenomic evidence for antibiotic-associated actinomycetes in the Karamay Gobi region.克拉玛依戈壁地区抗生素相关放线菌的宏基因组学证据。
Front Microbiol. 2024 Mar 5;15:1330880. doi: 10.3389/fmicb.2024.1330880. eCollection 2024.
9
Outer-Membrane Permeabilization, LPS Transport Inhibition: Activity, Interactions, and Structures of Thanatin Derived Antimicrobial Peptides.外膜通透性、LPS 转运抑制：Thanatin 衍生抗菌肽的活性、相互作用和结构。
Int J Mol Sci. 2024 Feb 9;25(4):2122. doi: 10.3390/ijms25042122.
10
BamA-targeted antimicrobial peptide design for enhanced efficacy and reduced toxicity.靶向 BamA 的抗菌肽设计以提高疗效和降低毒性。
Amino Acids. 2023 Oct;55(10):1317-1331. doi: 10.1007/s00726-023-03307-z. Epub 2023 Sep 5.
Initial Analysis of the Arylomycin D Antibiotics.
芳基霉素D类抗生素的初步分析
J Nat Prod. 2020 Jul 24;83(7):2112-2121. doi: 10.1021/acs.jnatprod.9b01174. Epub 2020 Jul 2.
4
An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria.一种具有抗多重耐药革兰氏阴性菌活性的两亲性肽。
Nat Commun. 2020 Jun 23;11(1):3184. doi: 10.1038/s41467-020-16950-x.
5
Multiple ways to kill bacteria via inhibiting novel cell wall or membrane targets.通过抑制新型细胞壁或细胞膜靶点来杀死细菌的多种方法。
Future Med Chem. 2020 Jul;12(13):1253-1279. doi: 10.4155/fmc-2020-0046. Epub 2020 Jun 15.
6
Structure of a nascent membrane protein as it folds on the BAM complex.新生膜蛋白在 BAM 复合物上折叠的结构。
Nature. 2020 Jul;583(7816):473-478. doi: 10.1038/s41586-020-2370-1. Epub 2020 Jun 11.
7
Thanatin Impairs Lipopolysaccharide Transport Complex Assembly by Targeting LptC-LptA Interaction and Decreasing LptA Stability.Thanatin通过靶向LptC-LptA相互作用并降低LptA稳定性来损害脂多糖转运复合物组装。
Front Microbiol. 2020 May 13;11:909. doi: 10.3389/fmicb.2020.00909. eCollection 2020.
8
The Science of Antibiotic Discovery.抗生素发现的科学。
Cell. 2020 Apr 2;181(1):29-45. doi: 10.1016/j.cell.2020.02.056. Epub 2020 Mar 19.
9
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
10
Antibiotics in the clinical pipeline in October 2019.2019 年 10 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10.